Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancerGOSS, P. E; FINE, S; GELMON, K et al.Cancer chemotherapy and pharmacology. 1997, Vol 41, Num 1, pp 53-60, issn 0344-5704Article

Breast carcinoma—rare types: review of the literatureYERUSHALMI, R; HAYES, M. M; GELMON, K. A et al.Annals of oncology. 2009, Vol 20, Num 11, pp 1763-1770, issn 0923-7534, 8 p.Article

Randomised placebo controlled trials in HIV infection: to be or not to be?GELMON, K; WELLER, I. V. D.Genitourinary medicine. 1989, Vol 65, Num 3, pp 143-145, issn 0266-4348, 3 p.Article

HIV and Kaposi's sarcomaMILLAR, J. L; GOLDSTEIN, D; GELMON, K. A et al.Medical journal of Australia. 1996, Vol 164, Num 9, pp 539-542, issn 0025-729XArticle

The sequential use of endocrine treatment for advanced breast cancer: where are we?BARRIOS, C; FORBES, J. F; HUDIS, C et al.Annals of oncology. 2012, Vol 23, Num 6, pp 1378-1386, issn 0923-7534, 9 p.Article

Pharmacologic insights into the future of trastuzumabLEYLAND-JONES, B; ARNOLD, A; GELMON, K et al.Annals of oncology. 2001, Vol 12, pp 43-47, issn 0923-7534, SUP1Conference Paper

In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell linesJOHNSTONE, S. A; GELMON, K; MAYER, L. D et al.Anti-cancer drug design. 2000, Vol 15, Num 2, pp 151-160, issn 0266-9536Article

A phase II trial of DuP 937 (Teloxantrone) in non-small cell lung cancerGREGG, R. W. C; KAIZER, L; FINE, S et al.Annals of oncology. 1993, Vol 4, Num 8, pp 693-694, issn 0923-7534Article

Subgroup effects in a randomised trial of different types and doses of exercise during breast cancer chemotherapyCOURNEYA, K. S; MCKENZIE, D. C; DOLAN, L. B et al.British journal of cancer. 2014, Vol 111, Num 9, pp 1718-1725, issn 0007-0920, 8 p.Article

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival : an overview of the randomised trials. CommentaryCHIA, S; BRYCE, C; GELMON, K et al.Lancet (British edition). 2005, Vol 365, Num 9472, pp 1665-1666, issn 0140-6736, 33 p.Article

Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancerGELMON, K; EISENHAUER, E; BATIST, G et al.Journal of clinical oncology. 1999, Vol 17, Num 10, pp 3038-3047, issn 0732-183XArticle

Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injectionEMBREE, L; GELMON, K; TOLCHER, A et al.Cancer chemotherapy and pharmacology. 1998, Vol 41, Num 5, pp 347-352, issn 0344-5704Article

Osteoblastic metastases from breast carcinoma with false-negative bone scanMUNK, P. L; POON, P. Y; O'CONNELL, J. X et al.Skeletal radiology. 1997, Vol 26, Num 7, pp 434-437, issn 0364-2348Article

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)CARDOSO, F; COSTA, A; CARDOSO, M. J et al.Annals of oncology. 2014, Vol 25, Num 10, pp 1871-1888, issn 0923-7534, 18 p.Article

Targeting triple-negative breast cancer: optimising therapeutic outcomesGELMON, K; DENT, R; MACKEY, J. R et al.Annals of oncology. 2012, Vol 23, Num 9, pp 2223-2234, issn 0923-7534, 12 p.Article

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy receivedDAWSON, S.-J; MAKRETSOV, N; CALLAGY, G et al.British journal of cancer. 2010, Vol 103, Num 5, pp 668-675, issn 0007-0920, 8 p.Article

Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy : a prospective studyYERUSHALMI, R; KRAMER, M. R; RIZEL, S et al.Annals of oncology. 2009, Vol 20, Num 3, pp 437-440, issn 0923-7534, 4 p.Article

New combination of the old drugs for elderly patients with small-cell lung cancer : A phase II study of the PAVE regimenWESTEEL, V; MURRAY, N; GODDARD, K et al.Journal of clinical oncology. 1998, Vol 16, Num 5, pp 1940-1947, issn 0732-183XArticle

Modulation of doxorubicin resistance in P388/ADR cells by Ro44-5912, a tiapamil derivativeDE JONG, G; GELMON, K; BALLY, M et al.Anticancer research. 1995, Vol 15, Num 3, pp 911-916, issn 0250-7005Article

Efficacy of weekly cisplatin-based chemotherapy in recurrent and metastatic head and neck cancerOSOBA, D; BAND, P. R; GOLDIE, J. H et al.Annals of oncology. 1992, Vol 3, pp 57-62, issn 0923-7534, SUP3Conference Paper

Biweekly paclitaxel and cisplatin : a phase I/II study in the first-line treatment of metastatic breast cancerO'REILLY, S; GELMON, K. A.Seminars in oncology. 1995, Vol 22, Num 3, pp 109-111, issn 0093-7754, SUP6Conference Paper

Interim results of a phase I/II study of biweekly paclitaxel and cisplatin in patients with metastatic breast cancerTOLCHER, A. W; GELMON, K. A.Seminars in oncology. 1995, Vol 22, Num 4, pp 28-32, issn 0093-7754, SUP8Conference Paper

Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality?YERUSHALMI, R; TYLDESLEY, S; WOODS, R et al.Annals of oncology. 2012, Vol 23, Num 4, pp 876-881, issn 0923-7534, 6 p.Article

Biweekly paclitaxel in the treatment of patients with metastatic breast cancerGELMON, K. A.Seminars in oncology. 1995, Vol 22, Num 5, pp 117-122, issn 0093-7754, SUP12Conference Paper

Page / 2